NSABP Objects to “Closed Process” For Review Of P-4 Breast Cancer Chemoprevention Trial.
NCI Barred PI Wolmark And Its Own Prevention Staff From Ad Hod Meeting.
NCI Director To Decide Fate Of P-4 After NCAB Meeting In June.
Paul Goss, Patricia Ganz Discuss Breast Cancer Prevention Trials.
Aranesp Study Finds No Difference In Survival Or Progression In Small-Cell Lung Cancer.
Trending Stories
- The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- Senators slam Bhattacharya for deflecting responsibility for NIH cuts, upheaval
Susan Collins: Trump’s 40% cut is “so disturbing” - In The Headlines: Increasing incidence of early-onset cancer is “a paradigm shift oncology isn’t quite prepared for”
- The Directors: Candace Johnson and Jonathan Friedberg on living through uncertainty at NCI, payment woes
Directors of two neighboring cancer centers in Upstate New York will face challenges, but “we’ll get through it” - NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Insights from ASCO 2025: Real-world evidence drives clinical decision-making